Gilead Sciences : Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

Kite, a Gilead Company , presented a new analysis today demonstrating that second-line Yescarta® therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma , even...

Read Full Article →